drugset
drugset / Trial / NCT04887064

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

NCT04887064 ↗

Phase 1 Completed 20 enrolled Amgen
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in participants with moderate or severe hepatic impairment compared to participants with normal hepatic function.

Timeline

Start
2021-04-22
Primary completion
2022-03-09
Completion
2022-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotorasib Small molecule — Oral

Indications

No indication recorded.